Sharemaestro company-news research for Pfizer Inc. (PFE), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
BUE
Argentina
Provisional evidence
Company news sentiment
Latest PFE news and sentiment
Pfizer Inc.
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
56 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone51/100
→
Published 30-day score50/100
Latest source headline
Are You Overpaying For Pfizer Stock Versus Its Rivals?
Trefis · 30 Sep 2026 15:29
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
56 current stories are mapped specifically to PFE.
The score uses 7 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.213.
Confidence is 22/100, below the threshold for a firm score.
50/100
News scoreEarly balanced news score
22/100
Confidencethin evidence
79%/100
Company news56 company stories
91/100
Story agreement9/100 difference
News history
Daily score and story count over 30 days
02 Sep17 Sep01 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence4
0.213 after freshness weightingSource breadth100
7 independent publishersCompany relevance79
share tied directly to this companyFreshness40
recency-weighted evidenceAgreement91
how closely stories agreePublisher mix79
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks24 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
03 Apr30 Jun25 Sep
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
25 Sep 202652ARS 11570.0+5.3%
18 Sep 202653ARS 10990.0-0.7%
11 Sep 202655ARS 11070.0-1.6%
04 Sep 202660ARS 11250.0+0.5%
28 Aug 202660ARS 11190.0+0.5%
21 Aug 202658ARS 11130.0+6.0%
14 Aug 202662ARS 10500.0-0.4%
07 Aug 202665ARS 10540.0+6.6%
Provisional evidence
News subjects
What is shaping the score
Earnings5020 stories · 36%
Market update5119 stories · 34%
Capital return466 stories · 11%
Deals and strategy505 stories · 9%
Regulatory and legal522 stories · 4%
Balance sheet502 stories · 4%
Guidance481 stories · 2%
Source mix
Where the evidence comes from
finance.yahoo.com4934 stories · 61%
Simply Wall St.564 stories · 7%
Trefis463 stories · 5%
seekingalpha.com533 stories · 5%
Zacks523 stories · 5%
Motley Fool472 stories · 4%
24/7 Wall St.502 stories · 4%
Recurring subjects
Subjects appearing most often
Pharma30Earnings24Dividends14Oncology13Healthcare10Fda Approval8Earnings Per Share7Clinical Trials7Biotech7Financial Results6
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
30 Jul50 neutral30 Sep 23:59
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 30 Sep 23:59 | 48 | -2 | 32/100 (+2) | 57 (-2) | Provisional |
| 29 Sep 23:59 | 50 | +0 | 30/100 (-2) | 59 (+1) | Provisional |
| 28 Sep 23:59 | 50 | +0 | 32/100 (-3) | 58 (+3) | Provisional |
| 27 Sep 23:59 | 50 | -2 | 35/100 (+6) | 55 (+1) | Provisional |
| 26 Sep 23:59 | 52 | +0 | 29/100 (-2) | 54 (-1) | Provisional |
| 25 Sep 23:59 | 52 | +1 | 31/100 (+1) | 55 (0) | Provisional |
| 24 Sep 23:59 | 51 | +0 | 30/100 (-2) | 55 (+1) | Provisional |
| 23 Sep 23:59 | 51 | +0 | 32/100 (0) | 54 (+1) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 56 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Earnings6 stories
31.9%38.7%
Capital return2 stories
16.6%0.0%
Market update2 stories
1.4%5.5%
Regulatory and legal1 story
0.0%5.9%
Each side uses the same scale: 0–38.7% of the retained directional evidence.
Where the influence comes from
33.3%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
—Unscored
Market updateNot used in direction
Are You Overpaying For Pfizer Stock Versus Its Rivals?
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 30 Sep 2026 15:29
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 0.6d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Moderna Sinks 6% on Citi Downgrade; Merck and Pfizer Stay Flat
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 30 Sep 2026 13:42
- News subject
- Market update
- Why this score
- Negative market reaction, Large negative market reaction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 0.7d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Novo vs. Pfizer: Which Large Drugmaker Offers Better Growth Prospects?
Novo NVO and Pfizer PFE are both pharmaceutical giants based in Denmark and the United States, respectively, with broad portfolios spanning major therapeutic areas. Novo is widely recognized for its leadership in diabetes and obesity, with its semaglutide franchise marketed under the Ozem…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Novo NVO and Pfizer PFE are both pharmaceutical giants based in Denmark and the United States, respectively, with broad portfolios spanning major therapeutic areas. Novo is widely recognized for its leadership in diabetes and obesity, with its semaglutide franchise marketed under the Ozempic and Rybelsus brands for type II diabetes (T2D) and Wegovy for chronic weight management. The company is also expanding its obesity offering with oral formulations, seeking to broaden its reach in the fast-growing weight-loss market. Pfizer, meanwhile, has traditionally maintained significant strength acros
- Published
- 29 Sep 2026 13:14
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 1.7d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Earnings GrowthEarnings Per ShareFda ApprovalFourth QuarterGuidanceObesity
—Unscored
Regulatory and legalNot used in direction
Pfizer, BioNTech, Moderna dealt blow in effort to dismiss mRNA patent lawsuits
[Intellectual Property mind map diagram with patent, trademark, copyright, license, infringement, trade secret on notepad] Ployker/iStock via Getty Images * A Delaware federal judge on Monday rejected requests from Pfizer (PFE [https://seekingalpha.com/symbol/PFE]), BioNTech (BNTX [https:…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
[Intellectual Property mind map diagram with patent, trademark, copyright, license, infringement, trade secret on notepad] Ployker/iStock via Getty Images * A Delaware federal judge on Monday rejected requests from Pfizer (PFE [https://seekingalpha.com/symbol/PFE]), BioNTech (BNTX [https://seekingalpha.com/symbol/BNTX]), and Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) to dismiss lawsuits filed against them by Bayer's (BAYZF [https://seekingalpha.com/symbol/BAYZF])(BAYRY [https://seekingalpha.com/symbol/BAYRY]) Monsanto unit regarding the drugmakers' use of a patent related to mRNA te
- Published
- 28 Sep 2026 20:38
- News subject
- Regulatory and legal
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 2.4d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
BiotechM APatent DisputeVaccines
—Unscored
EarningsNot used in direction
Pfizer (PFE) Heads To ESMO With 45 Oncology Abstracts And Fresh Cancer Data
Pfizer (NYSE:PFE) is set to feature data from 45 oncology research abstracts at the upcoming ESMO Congress. The company plans multiple oral presentations on late-stage cancer candidates alongside results for established oncology medicines. New clinical readouts at ESMO will spotlight Pfiz…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Pfizer (NYSE:PFE) is set to feature data from 45 oncology research abstracts at the upcoming ESMO Congress. The company plans multiple oral presentations on late-stage cancer candidates alongside results for established oncology medicines. New clinical readouts at ESMO will spotlight Pfizer's late-stage oncology pipeline and marketed cancer drugs, against a broader backdrop our research has surfaced. Take a look at 4 warning signs we have identified for Pfizer. For investors tracking how cancer research and drug discovery are changing, the wider healthcare AI trend is worth exploring through 3
- Published
- 28 Sep 2026 14:09
- News subject
- Earnings
- Why this score
- Negative financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 2.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
BiopharmaceuticalsClinical TrialsEarningsEsmoOncologyShare Price
—Unscored
Market updateNot used in direction
Pfizer Advances Today’s Cancer Care and Tomorrow's Potential Breakthroughs at ESMO
Data across 45 abstracts will highlight new evidence for established medicines, including PADCEV and TALZENNA, and promising late-stage pipeline candidates such as atirmociclib and tivunatamig (PF'4404) NEW YORK, September 28, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present da…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Data across 45 abstracts will highlight new evidence for established medicines, including PADCEV and TALZENNA, and promising late-stage pipeline candidates such as atirmociclib and tivunatamig (PF'4404) NEW YORK, September 28, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present data from 45 company-sponsored, investigator-sponsored, and collaborative research abstracts at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026 in Madrid, Spain. The presentations include 11 oral presentations spanning Pfizer's established medicines and late-stage pipe
- Published
- 28 Sep 2026 10:45
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 2.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Breast CancerClinical TrialsEsmo 2026Financial ResultsLung CancerOncology
—Unscored
EarningsNot used in direction
Gilead’s HIV Concentration or Pfizer’s Patent Cliff: Which Risk is Easier to Own?
Pfizer Inc. (NYSE:PFE) and Gilead Sciences, Inc. (NASDAQ:GILD) present investors with two very different forms of concentration risk. Pfizer needs newer medicines and its pipeline to offset revenue that will increasingly face generic and biosimilar competition, while Gilead has the opposi…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Pfizer Inc. (NYSE:PFE) and Gilead Sciences, Inc. (NASDAQ:GILD) present investors with two very different forms of concentration risk. Pfizer needs newer medicines and its pipeline to offset revenue that will increasingly face generic and biosimilar competition, while Gilead has the opposite problem, where its biggest franchise is performing extremely well, but HIV accounts for roughly three-quarters of its quarterly product sales. DON'T MISS: Pfizer vs. Johnson & Johnson: Which Pharma Giant Is Better Prepared for Its Patent Cliff? Neither risk should be ignored, but their latest results make o
- Published
- 27 Sep 2026 23:09
- News subject
- Earnings
- Why this score
- Negative financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 3.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsGuidancePharmaTotal Revenue
43/100 tone
Pfizer Inc. (NYSE:PFE) and Medtronic plc (NYSE:MDT) are both trying to prove that years of portfolio investment can translate into more durable growth, but the two healthcare giants are entering very different stages of their turnarounds. Pfizer is rebuilding around newer medicines as COV…
31.9% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Pfizer Inc. (NYSE:PFE) and Medtronic plc (NYSE:MDT) are both trying to prove that years of portfolio investment can translate into more durable growth, but the two healthcare giants are entering very different stages of their turnarounds. Pfizer is rebuilding around newer medicines as COVID revenue declines and generic and biosimilar competition approaches. Medtronic, meanwhile, is beginning to see faster growth from technologies it has spent years developing across cardiovascular devices, surgery and neuroscience. DON'T MISS: Pfizer vs. Johnson & Johnson: Which Pharma Giant Is Better Prepared
- Published
- 27 Sep 2026 22:57
- News subject
- Earnings
- Why this score
- Operating deterioration
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 44/100
- 30-day weight
- 31.9% of directional evidence · 3.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Cost ReductionEarningsEarnings GrowthFourth QuarterHealthcarePharma
—Unscored
EarningsNot used in direction
Pfizer vs. Thermo Fisher: Which Healthcare Turnaround has More Upside?
Pfizer Inc. (NYSE:PFE) and Thermo Fisher Scientific Inc. (NYSE:TMO) are both trying to put difficult post-pandemic periods behind them, but their recoveries look very different. Thermo Fisher is benefiting from improving activity across life-sciences markets after a prolonged slowdown in …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Pfizer Inc. (NYSE:PFE) and Thermo Fisher Scientific Inc. (NYSE:TMO) are both trying to put difficult post-pandemic periods behind them, but their recoveries look very different. Thermo Fisher is benefiting from improving activity across life-sciences markets after a prolonged slowdown in pharmaceutical and biotech spending. Pfizer, meanwhile, is trying to rebuild growth around newer medicines as COVID revenue fades and generic and biosimilar competition pressures parts of its older portfolio. DON'T MISS: Pfizer vs. Johnson & Johnson: Which Pharma Giant Is Better Prepared for Its Patent Cliff?
- Published
- 27 Sep 2026 22:51
- News subject
- Earnings
- Why this score
- Negative financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 3.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
BiotechEarningsLife SciencesPharmaTurnaround
—Unscored
EarningsNot used in direction
Pfizer (PFE) Balances Global Pricing Opportunity with New Revenue Sharing
Pfizer Inc. (NYSE:PFE) has agreed to share a portion of the incremental net revenue it generates from higher drug prices overseas with the U.S. Department of Health and Human Services (HHS), according to newly released documents covering its Most Favored Nation (MFN) pricing agreement. Th…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Pfizer Inc. (NYSE:PFE) has agreed to share a portion of the incremental net revenue it generates from higher drug prices overseas with the U.S. Department of Health and Human Services (HHS), according to newly released documents covering its Most Favored Nation (MFN) pricing agreement. The provision applies to medicines already on the market and runs from January 1, 2026, through January 20, 2029, although the revenue-sharing percentage and specific drugs covered remain redacted. HHS says the money will be used to lower costs for U.S. patients and taxpayers. The arrangement builds on Pfizer's
- Published
- 27 Sep 2026 20:27
- News subject
- Earnings
- Why this score
- Deteriorating financial comparison
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 3.4d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
International PricingPharmaRevenue SharingTariffsTotal Revenue
—Unscored
Balance sheetNot used in direction
Pfizer (PFE) Targets Air Traffic Fees Over Unpaid Vaccines. Can it Turn a Court Win Into Cash?
On September 13, 2026, the Wall Street Journal reported that Pfizer Inc. (NYSE:PFE) is enforcing a Belgian court judgment against Poland and Romania over unpaid COVID-19 vaccine orders by targeting an unusual source of leverage: air traffic control fees. Eurocontrol, the intergovernmental…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
On September 13, 2026, the Wall Street Journal reported that Pfizer Inc. (NYSE:PFE) is enforcing a Belgian court judgment against Poland and Romania over unpaid COVID-19 vaccine orders by targeting an unusual source of leverage: air traffic control fees. Eurocontrol, the intergovernmental body that coordinates European air traffic management, has frozen transfers of airline route charges owed to Poland's and Romania's air navigation agencies. It happened after Pfizer moved to enforce an April court ruling requiring the two countries to pay a combined roughly $2.1 billion for vaccine doses they
- Published
- 26 Sep 2026 03:06
- News subject
- Balance sheet
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 5.1d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Covid VaccineEuropeLawsuitPharmaRegulation
59/100 tone
Market update
Pfizer shares rose for seven consecutive sessions
Pfizer (PFE [https://seekingalpha.com/symbol/PFE]) shares clocked seven straight sessions of gains, as the stock was up 1% at $28.68 on Friday. The global biopharmaceutical company gained 2.8% in the preceding six sessions. The stock has surged over 13% so far this year. Looking at Seekin…
5.5% of directional evidence
Low story strength
Scoring detailsDirect company coverage
Pfizer (PFE [https://seekingalpha.com/symbol/PFE]) shares clocked seven straight sessions of gains, as the stock was up 1% at $28.68 on Friday. The global biopharmaceutical company gained 2.8% in the preceding six sessions. The stock has surged over 13% so far this year. Looking at Seeking Alpha's Quant Rating, PFE has a Hold rating [https://seekingalpha.com/symbol/PFE/ratings/quant-ratings] with a score of 3.4 out of 5. The company received A+ in the prospect of profitability, while it received F in growth factor. Turning to the Wall Street community [https://seekingalpha.com/symbol/PFE/ratin
- Published
- 25 Sep 2026 19:58
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 32/100
- 30-day weight
- 5.5% of directional evidence · 5.4d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
BiopharmaCost CuttingDividendsNew Drug PipelineOn The MoveRatings
—Unscored
Market updateNot used in direction
What Could Pfizer (PFE) Unlock From Faster FDA Reviews And Orphan Drug Growth?
Pfizer (NYSE:PFE) is focusing more of its research pipeline on therapies eligible for FDA Breakthrough Therapy and orphan drug status. The FDA has widened use of Breakthrough Therapy designations in areas such as oncology, which can shorten review and approval timelines. Global orphan dru…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Pfizer (NYSE:PFE) is focusing more of its research pipeline on therapies eligible for FDA Breakthrough Therapy and orphan drug status. The FDA has widened use of Breakthrough Therapy designations in areas such as oncology, which can shorten review and approval timelines. Global orphan drug markets are expanding in value as genomics, faster approvals, and government incentives support treatments for rare diseases. The growing role of Breakthrough Therapy labels and orphan drugs for Pfizer is important, but it should not dominate your thesis. Our analysis turns up 4 warning signs for Pfizer as w
- Published
- 25 Sep 2026 04:25
- News subject
- Market update
- Why this score
- Negative financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 6.1d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
BiotechFda ApprovalOncologyPharmaRare Diseases
—Unscored
EarningsNot used in direction
Could a New Vaccine Formula XFG Give Pfizer (PFE) and BioNTech (BNTX) a Post-Pandemic Revenue Boost?
Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced on August 27 that the U.S. FDA has approved the supplemental Biologics License Application for their 2026–2027 COVID-19 vaccine formula, COMIRNATY XFG. The updated formula targets the XFG variant and is authorized for adults a…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced on August 27 that the U.S. FDA has approved the supplemental Biologics License Application for their 2026–2027 COVID-19 vaccine formula, COMIRNATY XFG. The updated formula targets the XFG variant and is authorized for adults aged 65 and older, as well as individuals aged 5 to 64 with high-risk underlying conditions. Based on clinical, real-world, and manufacturing data demonstrating strong immune responses against circulating strains, the approval aligns with FDA strain guidance for fall 2026. You May Also Want to Look At: Pfizer (
- Published
- 24 Sep 2026 20:27
- News subject
- Earnings
- Why this score
- Contract or approval won
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 6.4d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Balance SheetCovid 19 VaccineFda ApprovalPharma
—Unscored
Market updateNot used in direction
Pfizer or AbbVie: Which Big Pharma Stock Is the Better Pick?
Pfizer PFE and AbbVie ABBV are two major U.S. drugmakers with diversified portfolios spanning several key therapeutic areas. Oncology accounts for roughly 27% of Pfizer's total revenues, while the company also has established franchises in inflammation and immunology, rare diseases and va…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Pfizer PFE and AbbVie ABBV are two major U.S. drugmakers with diversified portfolios spanning several key therapeutic areas. Oncology accounts for roughly 27% of Pfizer's total revenues, while the company also has established franchises in inflammation and immunology, rare diseases and vaccines. AbbVie, in contrast, has a strong presence in immunology, oncology and neuroscience, complemented by businesses in aesthetics and eye care. The company's newer immunology drugs, Skyrizi and Rinvoq, have more than offset the impact of Humira's loss of exclusivity (LOE), helping immunology account for ab
- Published
- 24 Sep 2026 14:45
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 6.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
DividendsEarningsImmunologyOncologyPharmaRevenue Growth
—Unscored
Market updateNot used in direction
Eli Lilly Vs. Pfizer in 2027: One Is a Much Better Place to Park Your Pharmaceutical Capital Next Year
Quick Read Lilly's incretin franchise hit ~$15B in a single quarter while LLY shares surged 56% over the past year, leaving PFE trading at just 9x forward earnings with a 6.22% yield. Retatrutide's BLA filing in Q1 2027 across obesity, sleep apnea, and osteoarthritis pain is Lilly's bigge…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Quick Read Lilly's incretin franchise hit ~$15B in a single quarter while LLY shares surged 56% over the past year, leaving PFE trading at just 9x forward earnings with a 6.22% yield. Retatrutide's BLA filing in Q1 2027 across obesity, sleep apnea, and osteoarthritis pain is Lilly's biggest swing catalyst, backed by 19 upward analyst EPS revisions in 30 days. Pfizer suits income investors seeking yield during a turnaround, but Lilly is the stronger 2027 growth pick if you can stomach the premium valuation. Just released. Our analysts combed the entire stock market and named the ten best stocks
- Published
- 23 Sep 2026 15:32
- News subject
- Market update
- Why this score
- Large positive market reaction, Positive market reaction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 7.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
DividendsEarningsEarnings ReportGrowthObesityPharma
—Unscored
EarningsNot used in direction
Pfizer (PFE) Stock May Be Overvalued After Overseas Pricing Deal
Pfizer has quietly put together a 23.9% gain over the past year, and that kind of move invites a closer look at whether the current share price lines up with what its earnings can support. With the stock recently closing at US$27.93, the question is how much of the latest news and revenue…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Pfizer has quietly put together a 23.9% gain over the past year, and that kind of move invites a closer look at whether the current share price lines up with what its earnings can support. With the stock recently closing at US$27.93, the question is how much of the latest news and revenue mix shifts are already reflected in that figure. The 23.9% 1 year return has reset expectations for Pfizer, which puts more weight on whether its earnings base can carry that higher price level. Fresh headlines around orphan drug opportunities and new revenue sharing agreements on overseas pricing can influen
- Published
- 23 Sep 2026 09:14
- News subject
- Earnings
- Why this score
- Negative valuation view
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 7.9d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsOrphan DrugsP E RatioPharmaShare PriceSplit
—Unscored
Company Logo Expedited FDA pathways are boosting oncology and rare-disease drug development, with gene therapy, immunotherapy and precision medicine creating key opportunities. Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Breakthrough Therapy (BT) Designation - Global Strategic Business Re…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Company Logo Expedited FDA pathways are boosting oncology and rare-disease drug development, with gene therapy, immunotherapy and precision medicine creating key opportunities. Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Breakthrough Therapy (BT) Designation - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Breakthrough Therapy (BT) Designation was estimated at US$79.7 Billion in 2025 and is projected to reach US$212.5 Billion by 2032, growing at a CAGR of 15.0% from 2025 to 2032. This comprehensive report provides an in-depth analys
- Published
- 23 Sep 2026 08:09
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 7.9d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
BiotechFda ApprovalImmunotherapyMarket Research ReportsOncologyRare Diseases
—Unscored
EarningsNot used in direction
Pfizer Invites Public to View and Listen to Webcast of November 3 Conference Call with Analysts
NEW YORK, September 22, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, November 3, 2026. The purpose of the call is to provide an update on …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
NEW YORK, September 22, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, November 3, 2026. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Third Quarter 2026 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.
- Published
- 22 Sep 2026 14:00
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 8.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
BiotechEarningsFinancial GuidanceFinancial ResultsPharma
43/100 tone
Key Points Interested in Pfizer Inc.? Here are five stocks we like better. Pfizer is reducing its reliance on COVID-19 products while reallocating resources toward newer and acquired medicines, vaccines and oncology products. COVID-related revenue is projected to decline from about $11 bi…
1.4% of directional evidence
Low story strength
Scoring detailsDirect company coverage
Key Points Interested in Pfizer Inc.? Here are five stocks we like better. Pfizer is reducing its reliance on COVID-19 products while reallocating resources toward newer and acquired medicines, vaccines and oncology products. COVID-related revenue is projected to decline from about $11 billion in 2024 to $4 billion in 2026. New and acquired products are becoming a larger growth engine, with international revenue rising from roughly $500 million in 2023 to $4 billion more recently. Pfizer has also cut costs, discontinued lower-return initiatives and significantly improved sales-force productivi
- Published
- 22 Sep 2026 12:02
- News subject
- Market update
- Why this score
- Negative financial language
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 27/100
- 30-day weight
- 1.4% of directional evidence · 8.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
China ExpansionObesity TreatmentsOncologyPharmaVaccines
—Unscored
Capital returnNot used in direction
AbbVie vs. Pfizer: Which Dividend Stock Is the Better Buy in September?
Dividend stocks are always great additions to a portfolio, as they offer investors the opportunity to earn passive income during any economic or market environment. This may compensate for weakness in your portfolio during tough market times and supercharge performance during better days …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Dividend stocks are always great additions to a portfolio, as they offer investors the opportunity to earn passive income during any economic or market environment. This may compensate for weakness in your portfolio during tough market times and supercharge performance during better days -- so you'll always be happy to hold onto at least a few of these players. Where to find dividend stocks? They're present throughout industries, but you'll notice many in the healthcare space. Generally, dividend players are well-established companies -- such as some of the world's top pharma names -- that don
- Published
- 22 Sep 2026 10:25
- News subject
- Capital return
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 8.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
DividendsFree Cash FlowHealthcarePharma
—Unscored
EarningsNot used in direction
Update: Pfizer Agrees to Share Incremental Overseas Drug Revenue With HHS
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 21 Sep 2026 17:40
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 9.5d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
EarningsNot used in direction
How Investors Are Reacting To Pfizer (PFE) Easing Policy Pressures And New HHS Revenue-Sharing Deal
Earlier this month, Pfizer's CEO Albert Bourla told investors at Morgan Stanley's Global Healthcare Conference that major headwinds such as tariffs, drug-pricing pressures, declining COVID-19 sales and upcoming patent expiries are beginning to ease, supported by cost actions and a growing…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Earlier this month, Pfizer's CEO Albert Bourla told investors at Morgan Stanley's Global Healthcare Conference that major headwinds such as tariffs, drug-pricing pressures, declining COVID-19 sales and upcoming patent expiries are beginning to ease, supported by cost actions and a growing mix of newer therapies. At the same time, Pfizer's agreement to share a portion of any additional overseas pricing revenue with the U.S. Department of Health and Human Services, alongside management's emphasis on protecting the dividend, offers fresh insight into how the company is balancing policy demands wi
- Published
- 21 Sep 2026 16:14
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 9.6d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
DividendsDrug PricingEarningsShareholder
—Unscored
EarningsNot used in direction
Huge News For Pfizer Stock Fans
This article first appeared on GuruFocus. Pfizer (NYSE:PFE) will share part of any additional revenue generated from higher drug prices overseas with the U.S. Department of Health and Human Services, according to a Sept. 19 report. The provision is included in Pfizer's most-favored-nation…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article first appeared on GuruFocus. Pfizer (NYSE:PFE) will share part of any additional revenue generated from higher drug prices overseas with the U.S. Department of Health and Human Services, according to a Sept. 19 report. The provision is included in Pfizer's most-favored-nation drug-pricing agreement with the U.S. government and applies to medicines already on the market. The arrangement runs from Jan. 1, 2026, through Jan. 20, 2029, according to documents released by Public Citizen after a Freedom of Information Act lawsuit. Warning! GuruFocus has detected 8 Warning Signs with PFE.
- Published
- 21 Sep 2026 14:40
- News subject
- Earnings
- Why this score
- Legal or regulatory risk
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 9.6d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Drug PricingHealthcareRegulation
41/100 tone
Capital return
What Would It Take For Pfizer To Cut Its Dividend?
12.8% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
- Published
- 21 Sep 2026 14:17
- News subject
- Capital return
- Why this score
- Dividend reduced
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 38/100
- 30-day weight
- 12.8% of directional evidence · 9.7d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
57/100 tone
[Pfizer sign outside a corporate office building on a sunny day] VIDOK/iStock Unreleased via Getty Images * The US Department of Health and Human Services will get a portion of the increased revenue if Pfizer (PFE [https://seekingalpha.com/symbol/PFE]) is able to charge higher drug prices…
13.2% of directional evidence
Low story strength
Scoring detailsDirect company coverage
[Pfizer sign outside a corporate office building on a sunny day] VIDOK/iStock Unreleased via Getty Images * The US Department of Health and Human Services will get a portion of the increased revenue if Pfizer (PFE [https://seekingalpha.com/symbol/PFE]) is able to charge higher drug prices abroad, according to a media report on Sunday. * The “most favored nation” contract was released on Saturday by the consumer watchdog organization Public Citizen, which obtained it after filing a Freedom of Information Act lawsuit. * The group released documents related to the Pfizer (PFE [https://seekingalph
- Published
- 21 Sep 2026 06:15
- News subject
- Earnings
- Why this score
- Improving financial comparison
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 35/100
- 30-day weight
- 13.2% of directional evidence · 10.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
PharmaPrice TargetRegulation
—Unscored
Market updateNot used in direction
Pfizer Says Its Biggest Headwinds Are Finally Easing. Does That Change the Story for This Ultra-High-Yield Dividend Stock?
The past few years have been challenging for Pfizer (NYSE: PFE). The company has faced macroeconomic problems, significantly lower sales from its coronavirus portfolio, and looming patent cliffs, including for its best-selling drug, the anticoagulant Eliquis. However, according to CEO Alb…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
The past few years have been challenging for Pfizer (NYSE: PFE). The company has faced macroeconomic problems, significantly lower sales from its coronavirus portfolio, and looming patent cliffs, including for its best-selling drug, the anticoagulant Eliquis. However, according to CEO Albert Bourla, Pfizer's headwinds are easing. Is he right?Image source: The Motley Fool. Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a
- Published
- 20 Sep 2026 21:20
- News subject
- Market update
- Why this score
- Negative financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 10.4d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
DividendsEarningsFinancial ResultsOncologyPatent CliffsPharma
57/100 tone
(Bloomberg) -- The US Department of Health and Human Services will get a portion of the increased revenue if Pfizer Inc. is able to charge higher drug prices abroad, according to newly released documents. Most Read from Bloomberg Saudis Give European Oil Buyers No Supplies for Next Month …
18.2% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
(Bloomberg) -- The US Department of Health and Human Services will get a portion of the increased revenue if Pfizer Inc. is able to charge higher drug prices abroad, according to newly released documents. Most Read from Bloomberg Saudis Give European Oil Buyers No Supplies for Next Month Zuckerberg Has an AI Empire to Build. Meet the Adviser Who Handles the Details Dubai Gains a Saudi Family Office as Exits From London Grow Air India CEO Weighs Folding Budget Unit Into Group to Cut Costs McDonald's Is Planning to Revamp Its Value Strategy to Revive US Sales The "most favored nation" contract w
- Published
- 19 Sep 2026 21:12
- News subject
- Earnings
- Why this score
- Improving financial comparison
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 36/100
- 30-day weight
- 18.2% of directional evidence · 11.4d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Drug PricingHealthcareTrade Negotiations
—Unscored
Capital returnNot used in direction
Pfizer (PFE), What Is Drawing Fresh Attention Now?
Pfizer (PFE) heads into its Morgan Stanley Global Healthcare Conference presentation on 14 September with investors watching how management frames dividend priorities, recent pipeline setbacks, and the evolving role of newer oncology partnerships. At a share price of US$27.64, Pfizer has …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Pfizer (PFE) heads into its Morgan Stanley Global Healthcare Conference presentation on 14 September with investors watching how management frames dividend priorities, recent pipeline setbacks, and the evolving role of newer oncology partnerships. At a share price of US$27.64, Pfizer has logged a 9.8% year to date share price return and a 22.5% total shareholder return over the past 12 months. This represents a rebound that has built momentum over the last three months as dividend messaging, Q2 guidance revisions, sector strength and fresh oncology deals have shifted how investors are weighing
- Published
- 18 Sep 2026 15:13
- News subject
- Capital return
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 12.6d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Balance SheetDividendsEarningsIntrinsic ValueOncologyPharmaceuticals
—Unscored
EarningsNot used in direction
Pfizer’s Dividend Yield Is Enormous. But Is the Payout Still Growing?
Quick Read Pfizer's 6.20% yield is real and covered by adjusted EPS guidance of $2.80 to $3.00, though its decade-long annual raise streak has stalled at $0.43. Merck raised its quarterly to $0.85 and Bristol-Myers Squibb to $0.63, while Comirnaty and Paxlovid revenue collapses froze Pfiz…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Quick Read Pfizer's 6.20% yield is real and covered by adjusted EPS guidance of $2.80 to $3.00, though its decade-long annual raise streak has stalled at $0.43. Merck raised its quarterly to $0.85 and Bristol-Myers Squibb to $0.63, while Comirnaty and Paxlovid revenue collapses froze Pfizer's payout. CEO Albert Bourla pledged Pfizer will maintain and eventually resume growing the dividend once its loss-of-exclusivity period clears. Read More: Learn 7 secret wealth tips high net worth investors use that most investors miss (sponsor) A 6.20% dividend yield in big pharma usually means one of two
- Published
- 18 Sep 2026 15:06
- News subject
- Earnings
- Why this score
- Negative financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 12.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
DividendsEarningsPharma
Earlier company news
PFE news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 113 older PFE headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to PFE, but the headline and available text are not mainly about Pfizer Inc.. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of PFE sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.